Precigen, Inc. (PGEN)

NMS – Real vaqt narxi. Valyuta: USD

5.86

+0.34 (6.16%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

5.90

+0.04 (0.68%)

Bozor oldidan: Jun 29, 2026, 5:58 AM EDT

15.06.2026

Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging

Meg Flippin, Benzinga Staff Writer Data reviewed by Dr. Helen Sabzevari at last week's Goldman Sachs healthcare conference suggests potential of extended surgical holidays for patients with RRP, a rare respiratory disease GERMANTOWN, MD / ACCESS Newswire / June 15, 2026 / Precigen Inc. (NASDAQ:PGEN) has gained an important advantage in the marketing of its new treatment for adults with recurrent respiratory papillomatosis (RRP), a rare and debilitating disease of the respiratory tract. The commercial-stage precision medicines company was just granted orphan drug exclusivity by the FDA for PAPZIMEOS™ (zopapogene imadenovec-drba), its treatment for RRP, a disease that typically requires patients to undergo multiple surgeries each year to remove benign tumors called papillomas that grow in the respiratory tract.

12.06.2026

Is Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares?

41,884 shares were sold in an open-market transaction for a total of ~$183,000 on May 28, 2026. The sale reduced direct holdings by 7.0%, from 596,419 shares to 554,535 shares, with no change to indirect ownership.

11.06.2026

Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices

Third annual RRP Awareness Day highlights the experiences of people living with recurrent respiratory papillomatosis and marks the next era following the first FDA-approved treatment for adults with RRP GERMANTOWN, Md. and FORT WORTH, Texas, June 11, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients and the Recurrent Respiratory Papillomatosis Foundation (RRPF), today announced continued collaboration in recognition of the third annual International RRP Awareness Day.

08.06.2026

Precigen, Inc. (PGEN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

01.06.2026

Precigen, Inc. (PGEN) is a Great Momentum Stock: Should You Buy?

Does Precigen, Inc. (PGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

30.05.2026

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

15 out of 18 complete responders, or 83%, demonstrated ongoing complete responses for at least 36 months without any additional treatment for RRP 5 complete responders have ongoing responses beyond 4 years Follow-up is ongoing; median duration of complete response has not yet been reached No new adverse safety events have been observed during long-term follow-up US FDA granted seven-year period of orphan drug market exclusivity to PAPZIMEOS GERMANTOWN, Md., May 30, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced updated long-term follow-up data from the pivotal study of PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP).

27.05.2026

Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States

FDA grants orphan drug exclusivity for PAPZIMEOS for the treatment of adults with recurrent respiratory papillomatosis Seven-year period of PAPZIMEOS market exclusivity is effective through August 14, 2032 PAPZIMEOS, the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis, is commercially available in the US GERMANTOWN, Md., May 27, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has granted orphan drug exclusivity for PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP).

Videolar

No Data

There is no data to display

Press-relizlar

15.06.2026

Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging

11.06.2026

Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices

30.05.2026

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

27.05.2026

Precigen, Inc. (PGEN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Precigen, Inc. (PGEN)

Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging

Is Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares?

Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices

Precigen, Inc. (PGEN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Precigen, Inc. (PGEN) is a Great Momentum Stock: Should You Buy?

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States

Videolar

No Data

Press-relizlar

Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging

Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States

Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging

Is Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares?

Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices

Precigen, Inc. (PGEN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Precigen, Inc. (PGEN) is a Great Momentum Stock: Should You Buy?

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States

Videolar

No Data

Press-relizlar

Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging

Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States

Search stocks

Precigen, Inc. (PGEN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Precigen, Inc. (PGEN)

Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging

Is Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares?

Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices

Precigen, Inc. (PGEN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Precigen, Inc. (PGEN) is a Great Momentum Stock: Should You Buy?

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States

Videolar

No Data

Press-relizlar

Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging

Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States

Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging

Is Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares?

Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices

Precigen, Inc. (PGEN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Precigen, Inc. (PGEN) is a Great Momentum Stock: Should You Buy?

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States

Videolar

No Data

Press-relizlar

Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging

Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States